Skip to main content
. Author manuscript; available in PMC: 2020 Feb 29.
Published in final edited form as: Adv Mater. 2018 Aug 31:e1803926. doi: 10.1002/adma.201803926

Figure 1.

Figure 1.

Schematic illustration of HRNMs for programmed CARIR chemotherapeutic delivery. The HRNMs show high stability in blood circulation (①) due to their nanoscale particle size and neutral POEG surface; therefore, they can effectively accumulate in the tumor via the EPR effect (②). In tumor microenvironment, acidic pH will cause charge conversion of the HRNMs and exposure of RGD peptides, permitting enhanced tumor retention (③) and cellular internalization (④). Thereafter, intracellular GSH will trigger CPT release for cancer chemotherapy (⑤).